pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·May 18·1 min read
save

CMS moves to allow lower-premium, less comprehensive ACA exchange plans starting 2027

May 18, 2026·read at STAT ↗RegulatoryNegative

The Centers for Medicare and Medicaid Services finalized a proposal that will let Affordable Care Act exchange plans offer more limited coverage and lower monthly premiums beginning in 2027.

The rule drops the requirement for standardized plan tiers and expands the availability of high‑deductible, catastrophic options beyond a narrow group of enrollees, reflecting the administration's goal of making policies cheaper.

Health policy experts warn that the reduced benefits could leave individuals and families facing large out‑of‑pocket bills if they need care, raising concerns about weakened consumer protections.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Trump’s CMS to allow skimpier plans on ACA exchanges”

read at STAT ↗
466 words · retrieved May 18
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Protara Therapeutics, Inc.7HOOKIPA Pharma Inc.2ASTRAZENECA
topics
Approval2Hypertension

related stories

  • Sep 23Amgen asset from $27.8B Horizon buy scores in Phase 3 Sjögren's studyBioSpace
  • Sep 22Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 winFierce Biotech
  • Sep 8Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapyBioPharma Dive
  • Sep 8STAT+: FDA approves AstraZeneca breast cancer drugSTAT
  • Aug 17STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefitSTAT